Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021011885 - CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER

Publication Number WO/2021/011885
Publication Date 21.01.2021
International Application No. PCT/US2020/042573
International Filing Date 17.07.2020
IPC
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 47/68 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
G01N 33/53 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Applicants
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US]
  • CONKLIN, Dylan [US]/[US]
  • PALAZZOLO, Michael, J. [US]/[US]
  • SLAMON, Dennis [US]/[US]
Inventors
  • CONKLIN, Dylan
  • PALAZZOLO, Michael, J.
  • SLAMON, Dennis
  • MCDERMOTT, Martina, S.
  • O'BRIEN, Neil, A.
Agents
  • HALSTEAD, David, P.
  • ABELLEIRA, Susan, M.
  • AKHIEZER, Alexander
  • CAI, Mi
  • CAO, Yichen
Priority Data
62/875,41617.07.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER
(FR) ANTICORPS DIRIGÉS CONTRE LA CLAUDINE 18 ET MÉTHODES DE TRAITEMENT DU CANCER
Abstract
(EN)
The present disclosure provides antigen-binding proteins which bind to Claudin- 18.2 (CLDN18.2); bispecific antigen-binding proteins which bind to CLDN18.2 and a second antigen; and conjugates thereof. In various aspects, the antigen-binding proteins bind to Extracellular Loop 1 (ELI) of the extracellular domain of CLDN18.2. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
(FR)
La présente invention concerne des protéines de liaison à l'antigène qui se lient à la claudine-18,2 (CLDN18.2) ; des protéines de liaison à l'antigène bispécifiques qui se lient à CLDN18.2 et un second antigène ; ainsi que des conjugués associés. Selon divers aspects de la présente invention, les protéines de liaison à l'antigène se lient à la boucle extracellulaire 1 (ELI) du domaine extracellulaire de CLDN18.2. L'invention concerne également des polypeptides, des acides nucléiques, des vecteurs, des cellules hôtes et des conjugués associés. L'invention concerne en outre des kits et des compositions pharmaceutiques comprenant de telles entités. L'invention concerne par ailleurs des procédés de préparation d'une protéine de liaison à l'antigène et des méthodes de traitement d'un sujet soufrant d'un cancer.
Latest bibliographic data on file with the International Bureau